123 related articles for article (PubMed ID: 34931381)
1. Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention.
Rosas RR; Nachbor KM; Handley N; Mathison G; Wuertz BR; Ba'th F; Ondrey FG
Head Neck; 2022 Mar; 44(3):661-671. PubMed ID: 34931381
[TBL] [Abstract][Full Text] [Related]
2. PPARγ-Mediated p21 Induction in Aerodigestive Preneoplastic Cell Lines.
Miller WA; Wuertz BR; Ondrey FG
Ann Otol Rhinol Laryngol; 2018 Oct; 127(10):677-686. PubMed ID: 30047791
[TBL] [Abstract][Full Text] [Related]
3. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
Chen JY; Wang JJ; Lee HC; Chi CW; Lee CH; Hsu YC
J Chin Med Assoc; 2020 Oct; 83(10):923-930. PubMed ID: 33009242
[TBL] [Abstract][Full Text] [Related]
4. PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques.
Handley N; Eide J; Taylor R; Wuertz B; Gaffney P; Ondrey F
Laryngoscope; 2017 Apr; 127(4):E124-E131. PubMed ID: 27896820
[TBL] [Abstract][Full Text] [Related]
5. Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor γ-dependent mechanism.
Uray IP; Rodenberg JM; Bissonnette RP; Brown PH; Mancini MA
Mol Pharmacol; 2012 Feb; 81(2):228-38. PubMed ID: 22053058
[TBL] [Abstract][Full Text] [Related]
6. The protective role of peroxisome proliferator-activated receptor gamma in lipotoxic podocytes.
Carrasco AG; Izquierdo-Lahuerta A; Valverde ÁM; Ni L; Flores-Salguero E; Coward RJ; Medina-Gómez G
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Jul; 1868(7):159329. PubMed ID: 37156296
[TBL] [Abstract][Full Text] [Related]
7. Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosis via PPARγ/ NF-κB signaling pathway in C6 glioma cells.
Hacioglu C; Kar F; Kacar S; Sahinturk V; Kanbak G
Med Oncol; 2021 Feb; 38(3):31. PubMed ID: 33599853
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Anticancer Agents Med Chem; 2021; 21(1):108-119. PubMed ID: 32807067
[TBL] [Abstract][Full Text] [Related]
9. Retinoids Augment Thiazolidinedione PPARγ Activation in Oral Cancer Cells.
Rosas R; Buryska S; Silver R; Wuertz B; Ondrey F
Anticancer Res; 2020 Jun; 40(6):3071-3080. PubMed ID: 32487601
[TBL] [Abstract][Full Text] [Related]
10. Identification of Bexarotene as a PPARγ Antagonist with HDX.
Marciano DP; Kuruvilla DS; Pascal BD; Griffin PR
PPAR Res; 2015; 2015():254560. PubMed ID: 26451138
[TBL] [Abstract][Full Text] [Related]
11. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer.
Park EY; Cho IJ; Kim SG
Cancer Res; 2004 May; 64(10):3701-13. PubMed ID: 15150131
[TBL] [Abstract][Full Text] [Related]
12. PPARγ in head and neck cancer prevention.
Burotto M; Szabo E
Oral Oncol; 2014 Oct; 50(10):924-9. PubMed ID: 24434068
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway.
Ai X; Mao F; Shen S; Shentu Y; Wang J; Lu S
BMC Cancer; 2018 Apr; 18(1):407. PubMed ID: 29642873
[TBL] [Abstract][Full Text] [Related]
14. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.
Lee G; Elwood F; McNally J; Weiszmann J; Lindstrom M; Amaral K; Nakamura M; Miao S; Cao P; Learned RM; Chen JL; Li Y
J Biol Chem; 2002 May; 277(22):19649-57. PubMed ID: 11877444
[TBL] [Abstract][Full Text] [Related]
15. PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model.
Dwyer-Nield LD; McArthur DG; Hudish TM; Hudish LI; Mirita C; Sompel K; Smith AJ; Alavi K; Ghosh M; Merrick DT; Tennis MA; Keith RL
Int J Cancer; 2022 Dec; 151(12):2195-2205. PubMed ID: 35830207
[TBL] [Abstract][Full Text] [Related]
16. Functional activation of PPARγ in human upper aerodigestive cancer cell lines.
Wright SK; Wuertz BR; Harris G; Abu Ghazallah R; Miller WA; Gaffney PM; Ondrey FG
Mol Carcinog; 2017 Jan; 56(1):149-162. PubMed ID: 26999671
[TBL] [Abstract][Full Text] [Related]
17. Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide.
Tang XH; Osei-Sarfo K; Urvalek AM; Zhang T; Scognamiglio T; Gudas LJ
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8907-12. PubMed ID: 24927566
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo.
Al-Taie OH; Graf T; Illert B; Katzenberger T; Mörk H; Kraus MR; Barthelmes HU; Scheurlen M; Seufert J
J Gastroenterol; 2009; 44(9):919-29. PubMed ID: 19506796
[TBL] [Abstract][Full Text] [Related]
19. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
20. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
Borbath I; Leclercq I; Moulin P; Sempoux C; Horsmans Y
Eur J Cancer; 2007 Jul; 43(11):1755-63. PubMed ID: 17582756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
